Online inquiry

IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15872MR)

This product GTTS-WQ15872MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ15872MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14265MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG-7116
GTTS-WQ4157MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI-754091
GTTS-WQ10084MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA L19TNF
GTTS-WQ6475MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CT-P-59
GTTS-WQ13963MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ15003MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ8514MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Hu3F8
GTTS-WQ3683MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 2287409
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW